Available as global and tech-only. Available as an add-on to the Standard Leukemia/Lymphoma Panel, and as stand-alone test (as described here) only for Breast capsules and fluids. Markers are CD3, CD4, CD7, CD8, CD25, CD26, CD30, CD45, CD279, and TRBC1 (10 markers).
This panel assesses T-cells for the presence of targetable antigens to guide therapeutic decisions. Expression of some markers may also help with differential diagnosis of various T-cell lymphomas or leukemias (including Mycosis fungoides/Sézary syndrome, anaplastic large cell lymphoma, angioimmunoblastic T cell lymphoma, etc.).
- Bone Marrow Aspirate: 1-2 mL EDTA. Sodium heparin is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.
- Peripheral Blood: 1-2 mL EDTA. Sodium heparin is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.
- Fresh Bone Marrow Core Biopsy: 1-2cm core (length) tissue in RPMI
- Fresh/Unfixed Tissue: 0.2 cm3 minimum in RPMI
- Fluids and FNAs: Equal parts RPMI and specimen volume
- CSF: 1-2 mL recommended
- NY Clients: Please provide Date and Time of Collection.
- Note: Please exclude biopsy needles, blades, and other foreign objects from transport tubes. These can compromise specimen viability and yield, and create hazards for employees.
Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability. Note: New York State samples must be received within 48 hours from collection per NYS requirements. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
24 hours